There are currently 1475 clinical trials in Dallas, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Texas Southwestern Medical Center, UT Southwestern Medical Center, UT Southwestern/Simmons Cancer Center-Dallas and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Heat Waves and the Elderly With COPD
NCT06295523
Recruiting
The purpose of this study is to investigate thermoregulatory responses in older individuals with COPD.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
03/04/2025
Locations: Texas Health Presbyterian Hospital Dallas, Dallas, Texas
Conditions: COPD, Aging, Hyperthermia
Register for Updates
Metabolic Characteristics of Brain Tumors Using Hyperpolarized Carbon-13 Magnetic Resonance Spectroscopic Imaging (MRSI)
NCT03067467
Recruiting
This is a non-randomized, purely observational, feasibility study to detect metabolic changes in patients with brain malignancy using a novel hyperpolarized \[1-13C\]pyruvate MRSI.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/03/2025
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Brain Tumor Adult
Register for Updates
Use of DNA Testing to Help Transition Kidney Transplant Recipients to Belatacept-only Immunosuppression
NCT04786067
Recruiting
The purpose of the study is to identify kidney transplant patients that can be transitioned from multi-drug immunosuppression therapy to Belatacept monotherapy, using cell free DNA and gene expression as markers of immune quiescence. The primary objective will be to determine if donor derived-cell free DNA (AlloSure) can be utilized to facilitate Belatacept monotherapy, and to determine if Belatacept is safe and effective as immunosuppression in kidney transplant recipients. The secondary object... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Kidney Transplant Immunosuppression
Register for Updates
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
NCT05259839
Recruiting
Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and toxicity of etentamig (ABBV-383) when co-administered with pomalidomide-dexamethasone (Pd), lenalidomide-dexamethasone (Rd), or daratumumab-dexamethasone (Dd), in adult participants with relapsed/refractory (R/R) multiple myeloma (MM). Adverse events and change in disease activity will be assessed. Etentamig is an investigati... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: University of Texas Southwestern Medical Center /ID# 243273, Dallas, Texas
Conditions: Relapsed/Refractory Multiple Myeloma
Register for Updates
Study to Assess EN3835 in the Treatment of Plantar Fibromatosis (Also Known as Ledderhose Disease)
NCT06151197
Recruiting
This study will assess the efficacy, safety, and tolerability of EN3835 compared to placebo in the treatment of PFI (also known as Ledderhose disease).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: Endo Site 25, Dallas, Texas
Conditions: Plantar Fibromatosis, Ledderhose Disease
Register for Updates
Multicomponent Intervention Study- Blood Donors With High Cholesterol
NCT05693701
Recruiting
The purpose and objective of this study is to improve cholesterol treatment among blood donors with FH (Familial Hypercholesterolemia).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/02/2025
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Lipid Metabolism Disorder
Register for Updates
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors
NCT02715284
Recruiting
This is a multi-center, open-label, first-in-human Phase 1 study evaluating the anti-programmed death receptor 1 (anti-PD-1) antibody dostarlimab (also known as TSR-042) n participants with advanced solid tumors who have limited available treatment options. The study will be conducted in 2 parts with Part 1 consisting of safety evaluation, pharmacokinetics (PK), and pharmacodynamics (PDy) of escalating doses of dostarlimab. Dose escalation will be based on ascending weight-based dose levels (DLs... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: GSK Investigational Site, Dallas, Texas +2 locations
Conditions: Neoplasms
Register for Updates
L-arginine to Reduce Sympathetic Nerve Activity in CKD Patients
NCT03982160
Recruiting
Chronic kidney disease (CKD) is associated with a higher risk of cardiovascular disease and death. An overactive sympathetic nervous system in CKD patients is one of the major mechanisms increasing the cardiovascular risks in this patient population. A potential signal driving sympathetic nerve activity (SNA) involves accumulation of the endogenous nitric oxide synthase (NOS) inhibitor asymmetric dimethylarginine (ADMA). ADMA is elevated in CKD and is a strong, independent predictor of future ca... Read More
Gender:
ALL
Ages:
Between 35 years and 75 years
Trial Updated:
02/28/2025
Locations: UT Southwestern, Dallas, Texas
Conditions: Chronic Kidney Disease
Register for Updates
Stereotactic Radiosurgery (SRS) Dose-Escalation Study for Brain Metastasis
NCT02645487
Recruiting
SRS dose escalation for brain metastases in radiation-naïve patients will establish true tolerable doses, which may exceed the current standard doses. This may lead to an improvement in local control, patient survival, and/or quality-of life.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Brain Neoplasms, Adult, Malignant
Register for Updates
DExterous Hand Control Through Fascicular Targeting (DEFT) - (Human Subjects)
NCT02994160
Recruiting
Our goal is to temporarily implant the following groups for 540 +/- 30 days: 1. Forearm FAST electrodes 1. Five human partial hand amputees (amputated at the level of the hand) with 2 FAST electrodes in the ulnar nerve and 2-5 FAST electrodes in the median nerve. 2. Five human hand and forearm amputees (amputated at the level of the forearm) with 2 FAST electrodes in the ulnar nerve and 2-5 FAST electrodes in the median nerve . 2. Arm FAST electrodes 1. Five human partial hand ampute... Read More
Gender:
ALL
Ages:
Between 18 years and 95 years
Trial Updated:
02/27/2025
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Amputation; Traumatic, Hand
Register for Updates
Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage
NCT03926624
Recruiting
Phase III, multicenter, randomized study with two arms (1:1 ratio) enrolling patients with AML relapsed/refractory after 2, 3, or 4 prior induction regimens: Experimental arm: DFP-10917 14-day continuous intravenous (IV) infusion at a dose of 6 mg/m²/day followed by a 14-day resting period per 28-day cycles. Control arm: Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High and Intermediate Dose Cytarabine Regimens), dependin... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: UT Southwestern, Dallas, Texas
Conditions: Leukemia, Myeloid, Acute
Register for Updates
A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)
NCT06339008
Recruiting
The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in adult participants with perennial allergic rhinitis. The study will last about 18 months
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: AARA Research Center, Dallas, Texas
Conditions: Perennial Allergic Rhinitis (PAR)
Register for Updates